Asthika Goonewardene analyst TRUIST

Currently out of the existing stock ratings of Asthika Goonewardene, 12 are a HOLD (12.63%), 83 are a BUY (87.37%).

Asthika Goonewardene

Work Performance Price Targets & Ratings Chart

Analyst Asthika Goonewardene works at TRUIST with a stock forecast success ratio of 33.39% fulfilled within 81.8 days on average.

Asthika Goonewardene’s has documented 188 price targets and ratings displayed on 20 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on CRBU, Caribou Biosciences at 16-May-2024.

Wall Street Analyst Asthika Goonewardene

Analyst best performing recommendations are on IMGN (IMMUNOGEN).
The best stock recommendation documented was for IOVA (IOVANCE BIOTHERAPEUTICS) at 12/27/2023. The price target of $17 was fulfilled within 62 days with a profit of $9.77 (135.13%) receiving and performance score of 21.8.

Average potential price target upside

ALLO Allogene Therapeutics CELU Celularity CGEN Compugen EXEL Exelixis GMAB Genmab AS HARP Harpoon Therapeutics IGMS IGM Biosciences IOVA Iovance Biotherapeutics STRO Sutro Biopharma TCRR Tcr2 Therapeutics HOOK Hookipa Pharma NXTC NextCure  AUTL Autolus Therapeutics Ltd TIL Instil Bio . SGEN Seagen ACET Adicet Bio ACLX Arcellx IMGN ImmunoGen MRSN Mersana Therapeutics CRBU Caribou Biosciences

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

9

$6.23 (224.91%)

10

2 days ago

0/6 (0%)

$5.99 (199.00%)

Buy

17

$14.23 (513.72%)

3 days ago

2/10 (20%)

$14.02 (470.47%)

94

Hold

4.6

$1.83 (66.06%)

5

4 days ago

3/8 (37.5%)

$1.64 (55.41%)

11

Buy

8

$5.23 (188.81%)

9

2 months 21 days ago

0/3 (0%)

$2.86 (55.64%)

Buy

10

$7.23 (261.01%)

12

3 months 29 days ago

1/7 (14.29%)

$6.91 (223.62%)

28

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Asthika Goonewardene is most bullish on?

Potential upside of $20.02 has been obtained for GMAB (GENMAB AS)

Which stock is Asthika Goonewardene is most reserved on?

Potential downside of -$0.01 has been obtained for HARP (HARPOON THERAPEUTICS)

What Year was the first public recommendation made by Asthika Goonewardene?

On 2020

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?